Although constipation and diarrhea may seem like opposite problems, they both hinge on the same underlying issue: how much fluid moves into the gut. These common issues affect millions of people in ...

The chief medical officer is interested in an easier path to market for health screening features in wearable devices.

A mini-review in Brain Medicine examines the distinct and often opposing roles of AMPKα1 and AMPKα2 isoforms in Alzheimer's ...

A research team maps the key tasks that define modern enzyme engineering—function annotation, structure modeling, and property prediction—and explain how AI methods now accelerate each step, from ...

Radiopharmaceutical therapy (RPT) offers molecular-targeted treatment strategies and presents an ideal model for advancing ...

Novo Nordisk has won the race to secure approval from the U.S. Food and Drug Administration for the first weight-loss drug to be administered orally. Jules Rimmer is a markets reporter in ...

Comprehensive Analysis of Tirzepatide Access Options as Resolution Season Peaks: MyStart Health Programs, FDA Context, Coverage Developments, and Questions to Consider Before Starting GLP-1 ...

Industry Analysis Examines How FDA's First Oral GLP-1 Approval, Published Clinical Trial Data, and Evolving Telehealth Access ...

After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making history again with the first FDA approval of a GLP-1 pill for weight loss.

Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it picked up a year ago, was hit with a warning letter from the FDA last month. The ...

Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal diabetes trials of an asset that it previously saw primarily as an obesity ...

The studies were a setback for the optimistic view that semaglutide and other drugs used in obesity and diabetes treatment could help prevent a number of brain diseases. By Gina Kolata Gina Kolata has ...